Printer Friendly

SYNERGEN APPOINTS VICE PRESIDENTS OF MARKETING AND SALES AND PROCESS ENGINEERING

 BOULDER, Colo., Feb. 10 /PRNewswire/ -- Synergen Inc. (NASDAQ: SYGN) announced today the promotion of two directors, Paul J. Hastings to vice president, marketing and sales and Geoffrey Slaff, Ph.D., to vice president, process engineering.
 In his new position, Mr. Hastings will continue to direct all marketing and sales activities in North America and will become more involved in the development of Synergen's international business opportunities. "Playing a central role in a critical company function, Paul has built an outstanding marketing and sales organization to meet the needs of a rapidly changing healthcare environment," said Gregory B. Abbott, executive vice president at Synergen.
 Before joining Synergen in 1990, Mr. Hastings held various management positions in sales, sales training and product marketing at Roche Laboratories, a division of Hoffmann-La Roche Inc. Mr. Hastings holds a degree in Pharmacy with an area of interest in Business Administration from the University of Rhode Island.
 Dr. Slaff came to Synergen from Schering-Plough Corp. as senior scientist in the protein purification area. As director of process engineering, Dr. Slaff directed the design and scale-up of production processes for all Synergen manufacturing plants in the United States, including the 75,000 square foot ANTRIL plant at LakeCentre in Boulder.
 "During his six years at Synergen, Geoff has made major contributions to the progress of our company. As we expand internationally, he will direct our production and process technology for additional manufacturing plants," said Mark D. Young, Ph.D., vice president, manufacturing and process development at Synergen.
 Dr. Slaff received a bachelor of science degree in Biochemistry from the University of California at San Diego and his masters and doctorate degrees in Chemical and Biochemical Engineering from the University of Pennsylvania.
 Synergen is a biopharmaceutical company engaged in the discovery, development and manufacture of protein-based pharmaceuticals. The company's research is targeted toward products for inflammatory diseases, tissue repair and neurological diseases. The company is headquartered in Boulder with manufacturing facilities in Boulder and Delaware and operations in The Hague and Kobe, Japan.
 -0- 2/10/93
 /CONTACT: Paul Laland (media), 303-541-1325, or Debra Bannister (financial), 303-938-6242, both of Synergen/
 (SYGN)


CO: Synergen Inc. ST: Colorado IN: MTC SU: PER

MC -- DV004 -- 4987 02/10/93 08:15 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 10, 1993
Words:371
Previous Article:FORD CREDIT REPORTS RECORD 1992 EARNINGS
Next Article:ATLAS CORPORATION REPORTS PRESIDENT RESIGNS; SUBSTANTIAL LOSSES CONTINUE
Topics:


Related Articles
SYNERGEN APPOINTS NATIONAL SALES MANAGER
SYNERGEN AWARDED THIRD CNTF PATENT
SYNERGEN COMPLETES BUYOUT OF R&D PARTNERSHIP
SYNERGEN APPOINTS HEADS OF CLINICAL RESEARCH AND REGULATORY AFFAIRS IN EUROPE
SYNERGEN REPORTS MANAGEMENT CHANGES
SYNERGEN REPORTS FIRST QUARTER FINANCIAL RESULTS
SYNERGEN INC. REPORTS THIRD QUARTER FINANCIAL RESULTS
SYNERGEN APPOINTS GREGORY ABBOTT CHIEF EXECUTIVE OFFICER
Biomira Appoints Chief Operating Officer.
ViaCell Names Paul Hastings to Board of Directors.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters